Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 592 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/1/2002 First Published: 12/1/2000


1.		Phase IV Study of Low-Dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				CWRU-CHIR-1899 CHIR-MA-99-01, CWRU-010002, NCI-G00-1875, NCT00006864

Last Modified: 9/1/1995


2.		Phase II/III Randomized Study of CD8+ TIL/IL-2 for Metastatic Renal Cell Carcinoma (Summary Last Modified 09/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				AIS-1061-9320 NCI-V95-0689

Last Modified: 12/24/2008


3.		Phase II/III Randomized Study of Adjuvant Active Specific Immunotherapy with Autologous Tumor Cells and BCG plus CTX and Low-Dose IL-2 for Stage II/III Renal Cell Adenocarcinoma (Summary Last Modified 09/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 75								CNR-9505 EU-95023

Last Modified: 9/22/2005


4.		Phase II/III Randomized Study of Interleukin-2 and Interferon alfa With Versus Without Fluorouracil for Metastatic Renal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 79								FRE-FNCLCC-95009 EU-96026

Last Modified: 10/19/2006


5.		Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Renal Cell Carcinoma --- A Modified Group C Study (Summary Last Modified 04/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				16 and over								NCI-C87-0001 AECM-8706153, CHNMC-COH-7077, CMGH-8756-S-87A, CWRCC-0987188, DUMC-7988710, FCCC-88982, IDB-MGC-RENAL/RAND, JHOC-87092507, MDA-DM-87059, UAC-345, UCCRC-4998, UPCC-1887, UUMC-2056, VRCC-CHRMS-8831, WSU-C-70387, YALE-HIC-4454, C87-0001

Last Modified: 10/19/2006


6.		Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Malignant Melanoma --- A Modified Group C Study (Summary Last Modified 04/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				16 and over								NCI-C87-0002 AECM-8706152, CHNMC-COH-7075, CMGH-8755-S-87A, CWRCC-0787137, DUMC-7958710, IDB-MGC-MEL/RAND, JHOC-87092508, MDA-DM-87056, UAC-343, UCCRC-4985, UKMC-8800110, UPCC-1687, UUMC-2055, VRCC-CHRMS-8832, WSU-C-70487, YALE-HIC-4455, C87-0002

Last Modified: 1/1/1988


7.		Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Carcinoma of the Colon (Summary Last Modified 01/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70								UCCRC-4973A NCI-V87-0310

Last Modified: 1/1/1988


8.		Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Malignant Melanoma (Summary Last Modified 01/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70								UCCRC-4973B NCI-V87-0311

Last Modified: 4/26/2007


9.		Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Renal Cell Carcinoma (Summary Last Modified 01/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70								UCCRC-4973C NCI-V87-0312

Last Modified: 11/1/1990


10.		Phase II/III Adoptive Immunotherapy for Metastatic Renal Cell Carcinoma: Systemic IL-2 plus IL-2-Activated/Periodate-Treated Cells (Summary Last Modified 11/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				21 to 70								NYH-1088-350CRC NCI-V88-0417

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute